Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025Expert Opinion on Emerging Drugs

Emerging drugs for the treatment of bullous pemphigoid: what’s new on the horizon?

View Full Paper
Ask AI
Bookmark
Share

Authors

HOHenning OlbrichCSChristian D. Sadik

Discussion

Loading...

Member takes

Overview

This review discusses new drug trials targeting eosinophils and neutrophils in bullous pemphigoid, highlighting recent challenges.

Key Points

  • Current research shows modest success in targeting IL-4/IL-13 signaling in bullous pemphigoid treatment.
  • Only dupilumab achieved its primary endpoint in bullous pemphigoid, while other drug strategies largely failed.
  • Targeting neutrophils presents a new avenue of potential treatments for bullous pemphigoid, diverging from previous approaches.
  • Inhibitors of specific kinases may offer new therapeutic options by impacting multiple immune cells in bullous pemphigoid.

Cite This Study

Olbrich et al. (2025) studied this question.

synapsesocial.com/papers/68bb42272b87ece8dc958e5ahttps://doi.org/10.1080/14728214.2025.2555080
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Emerging Therapeutic Landscape of Bullous Pemphigoid: A Systematic Registry‐Based Analysis of Clinical Trials (2015–2025)2026
  2. 2An overview of bullous pemphigoid2024
  3. 3Efficacy of omalizumab for the treatment of bullous pemphigoid: Spanish multicentre real-world experience2024 · 8 citations
  4. 4Immunophenotypic and Transcriptomic Analysis of Peripheral Blood Mononuclear Cells in Bullous Pemphigoid2025 · 1 citations
  5. 5Dupilumab for Drug-Induced Bullous Pemphigoid: A Case Series and Literature Review2026